Hill Publishing Group | contact@hillpublisher.com

Hill Publishing Group

Location:Home / Journals / International Journal of Clinical and Experimental Medicine Research /


Vaccination Adverse Outcomes and Costs of Vaccine Injury Claims (VICs): Past, Present and Covid-19

Date: December 11,2020 |Hits: 3933 Download PDF How to cite this paper

John Paull

University of Tasmania, Hobart, Tasmania, Australia.

*Corresponding author: John Paull


The US National Vaccine Injury Compensation Program (VICP) has paid out US$4,431,468,456 for 7,575 vaccine injuries from (financial years) 1989 through 2020. The average settled claim was US$585,012 per claimant. Of the total claims filed (n=22,372), 94% were claims for non-fatal injury (n=21,035) and 6% were claims for death (n=1,337). Of the total claims filed, 34% were successful (n=7,611), 52% were dismissed (n=11,671), and 14% were not progressed (n=3,090). The VICP acts as an indemnity shield for the vaccine industry. The VICP offers a non-litigious path to compensation for the vax-injured. The VICP is funded by a vax tax of US 75 cents per disease per dose. Injury claims can be rejected because the claim is filed out of time, the particular vaccine is not a VICP-listed vaccine, the injury is not a VICP-listed injury (e.g. autism is not listed), or the injury is not sufficiently severe. There were 1.39 compensated injuries per one million distributed vaccine doses (n=5,233 compensated injuries for 3,761,744,351 distributed vaccine doses; 2006 through 2018). The VICP payout rate is US$813 million for vax injuries per one billion vax doses. Based on past experience of vaccination injury, mass vaccination of billions of people for Covid-19 can be anticipated to produce vaccine injuries (including deaths). Based on the historical data of the VICP across 30 different vaccines, vaccinating a billion people with Covid-19 vaccines, can be anticipated to manifest a scenario of US$813 million of vaccine injuries (as an underestimate). Vaccinating the world’s population (n=7.8 billion) with an initial Covid-19 vaccine dose may generate US$6.3 billion of vaccine injuries. A two dose Covid-19 vaccine (prime-boost regimen) may generate US$12.7 billion of vaccine injuries. A Covid-19 vax regime of (say) three booster shots may generate US$25.4 billion of vaccine injuries. These scenario extrapolations assume that the Covid-19 vaccines (although developed and administered under pandemic duress), are neither more nor less injurious than the vaccines (n=30) of VICP experience, which have been tested, certified, manufactured, stored and administered to US standards, and that there is no differential between the compensable value of US and non-US injuries.


[1] Friedman, M. (1975). There’s No Such Thing as a Free Lunch. Chicago, IL: Open Court Publishing Company.

[2] Slaoui, M. and M. Hepburn. (2020). Developing Safe and Effective Covid Vaccines—Operation Warp Speed’s Strategy and Approach. The New England Journal of Medicine, 2020, 383(29 October): 1701-1703.

[3] CNN, The Situation Room: U.S. Death Toll Tops 192,000 with over 6.4 Million Cases; One- on-One with Dr. Anthony Fauci; Rep. Nancy Pelosi (D-CA) Is Interviewed About The 9/11 Attacks, Disunity Amid Coronavirus Pandemic; Prosecutor In Dur-ham Investigation Of Russia Probe Origins Resigns, Reportedly Due In Part To Pressure To Wrap Up Before Election. Aired 5-6p ET. 2020, 11 September. Atlanta, GA: CNN Transcripts.

[4] Colorossi, N. (2020). How long it took to develop 12 other vaccines in history. Business Insider Australia, 2020. July 18.

[5] CDC, Coronavirus Disease 2019 (COVID-19): Frequently Asked Questions about COVID-19 Vaccination. 2020, 14 October. Atlanta, GA: Centers for Disease Control and Prevention (CDC).

[6] Hart, E. M. (2020). Rapid response to: Covid-19: Less haste, more safety. British Medical Journal, 2020. 1 September. 379(m3258).

[7] Corum, J., S.-L. Wee, and C. Zimmer. (2020). Coronavirus Vaccine Tracker. The New York Times, 2020. 28 October.

[8] WHO, Global Vaccine Market Report. (2019, December). Geneva: World Health Organization (WHO).

[9] Mikulic, M. (2019). Global Vaccine Market Revenues 2014-2020. 2019, Hamburg, DE: Statista.

[10] Wood, N. (2020). Australia needs a vaccine injury compensation scheme: Upcoming COVID-19 vaccines make its introduction urgent. Australian Journal of General Practice, 2020, 49(Suppl. 36): 1-2.

[11] DoJ, Vaccine Injury Compensation Program. (2018). Washington, DC: United States Department of Justice (DoJ).

[12] HRSA, Data & Statistics. 2020, 1 October 2020 update. Rockville, MD: Health Resources & Services Administration (HRSA).

[13] Worldometer, Current World Population: 7,821,697,000. 2020, worldometers.info (accessed 29 Oct 2020).

[14] Worldometer, Countries in the World: 195. 2020, worldometers.info (accessed 29 Oct 2020).

[15] McNamara, A. Multiple vaccine doses could be necessary to protect from coronavirus, Bill Gates says. McNamara, Audrey, 23 July. New York, NY: CBS News.

[16] HRSA, Vaccine Injury Table. (2017). Rockville, MD: Health Resources & Services Administration (HRSA).

[17] Carabin, H., et al. (2002). The average cost of measles cases and adverse events following vaccination in industrialised countries. BMC Public Health, 2002, 2(22): 1-13.

[18] Khamsi, R. (2020). If a coronavirus vaccine arrives, can the world make enough? Researchers warn production constraints and hoarding could limit SARS-CoV-2 vaccine supplies. Nature, 2020, 580: 578-580.

[19] Paull, J. (2020). Science Versus Public Sentiment: “Covid-19 is not a Bioweapon Created in a Laboratory, Say UK Scientists”, “Nope, Don’t Believe It”, Say UK Public. International Journal of Clinical and Experimental Medicine Research, 2020, 4(3): 93-100.

[20] WHO. (2020). Improving vaccination demand and addressing hesitancy. Geneva: World Health Organization.

How to cite this paper

Vaccination Adverse Outcomes and Costs of Vaccine Injury Claims (VICs): Past, Present and Covid-19

How to cite this paper: John Paull. (2021) EVaccination Adverse Outcomes and Costs of Vaccine Injury Claims (VICs): Past, Present and Covid-19. International Journal of Clinical and Experimental Medicine Research, 5(1), 1-5.

DOI: http://dx.doi.org/10.26855/ijcemr.2021.01.001

Volumes & Issues

Free HPG Newsletters

Add your e-mail address to receive free newsletters from Hill Publishing Group.

Contact us

Hill Publishing Group

8825 53rd Ave

Elmhurst, NY 11373, USA

E-mail: contact@hillpublisher.com

Copyright © 2019 Hill Publishing Group Inc. All Rights Reserved.